TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06752902

Intervention type: OTHER
Group type: OTHER
Intervention: Standard Care Arm
Description: standard care combined with personalised prevention

Intervention type: OTHER
Group type: OTHER
Intervention: standard care combined with personalised prevention
Description: standard care combined with personalised prevention
Study: NCT06751810

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Food supplement
Description: The nutritional composition of the food supplement comprises:~(i) butyric acid or butyrate, (ii)inactivated Lactobacillus rhamnosus GG (iii) a Perilla frutescens dry extract, and (iv) quercetin.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT06754410

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamsulosin
Description: group A take tamsulosin once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetirizine
Description: give cetirizine once dailly

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Cetirizine + Tamsulosin
Description: both once daily

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: once dailly
Study: NCT06753929

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: wireless wearable thermal anisotropy measurement device
Description: non-invasive device used for assessing CSF shunt flow via thermal anisotropy measurements in a routine outpatient clinic setting
Study: NCT05787171

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WE-MBVMS using suture Vicryl (Polyglactin 910; Johnson & Johnson International, USA);
Description: The skin around the incision is dissociated from the bottom, followed by measuring the length of the wound and dividing it into three segments evenly. Each segment randomly received 2-0 Vicryl suture, 2-0 PDS suture, or 2-0 Ethibond suture to sew up the incision with WE-MBVMS.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WE-MBVMS using suture PDS (polydioxanone; Johnson & Johnson International, USA)
Description: The skin around the incision is dissociated from the bottom, followed by measuring the length of the wound and dividing it into three segments evenly. Each segment randomly received 2-0 Vicryl suture, 2-0 PDS suture, or 2-0 Ethibond suture to sew up the incision with WE-MBVMS.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WE-MBVMS using suture Ethibond (polyester; Johnson & Johnson International, USA）
Description: The skin around the incision is dissociated from the bottom, followed by measuring the length of the wound and dividing it into three segments evenly. Each segment randomly received 2-0 Vicryl suture, 2-0 PDS suture, or 2-0 Ethibond suture to sew up the incision with WE-MBVMS.
Study: NCT04743453

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Dapagliflozin 10 mg: Study drug will be administered by once-daily orallly. The first dose MUST be started within 1 and 7 days after randomization. The subsequent doses will be administered 24 ± 4 hours after the previous dose.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered by once-daily orallly. The first dose MUST be started within 1 and 7 days after randomization. The subsequent doses will be administered 24 ± 4 hours after the previous dose.
Study: NCT05483192

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Oral Dyglomera
Description: Measurement of body weight, waist circumference, hip circumference, waist to hip ratio, body mass index, body fat.~Blood draw and measurement of blood total Cholesterol, HDL-cholesterol, LDL-cholesterol), ALT, AST, Fasting Blood Glucose, CRP, adiponectin, and leptin.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Oral Dyglomera
Description: Measurement of body weight, waist circumference, hip circumference, waist to hip ratio, body mass index, body fat.~Blood draw and measurement of blood total Cholesterol, HDL-cholesterol, LDL-cholesterol), ALT, AST, Fasting Blood Glucose, CRP, adiponectin, and leptin.
Study: NCT06754644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QL2107
Description: 200mg on day 1 of each 21-day cycle of the study

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: 500 mg/m2 on Day 1 of each 21-day cycle of the study
Study: NCT06195878

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP Therapy
Description: Continuous positive airway pressure (CPAP) therapy in the management of moderate-to-severe sleep-related breathing disorders (SRBDs)/sleep apnea.
Study: NCT04607837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etrasimod
Description: Etrasimod 2 mg tablet by mouth, once daily up to 52 weeks of treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Etrasimod matching placebo tablet by mouth, once daily up to 52 weeks of treatment
Study: NCT06165120

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bracka's repair using preputial graft
Description: Staged repair:~1. Correction of ventral chordee: by degloving of the penile skin, transection of the urethral plate \&/or ventral corporotomy through the tunica albuginea. This will be according to the degree of ventral chordee after artificial erection test.~2. Preputial graft placement: a graft will be designed on the inner layer of the preputial hood, according to the length of the urethra defect. Fixation of the free graft will be performed along the whole defective urethral plate. A compression dressing will be used for the transplanted graft. At the end of the surgery, a urinary catheter will be placed through the ectopic meatus.~3. Tubularisation of the graft: this stage will be performed 6 months later. The new graft will be tubularised over a catheter. Then a protective layer may be made over the tubularization using a dartos or tunica vaginalis flap. After suturing of the penile skin and dressing of the penis, a urethral catheter would be retained for urinary diversion.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: STPIF (Staged Transverse Preputial Island Flap) repair using preputial flap
Description: Staged repair:~1. Correction of ventral chordee; by degloving of the penile skin, transection of the urethral plate \&/or ventral corporotomy through the tunica albuginea. This will be according to the degree of ventral chordee after artificial erection test.~2. Preputial flap placement: according to the distance between the ectopic meatus and the glans tip, a transverse rectangular flap will be dissected from the inner layer of the dorsal prepuce. The flap will be placed along the defective urethral plate. Eventually, a silicon indwelling catheter will be placed through the ectopic meatus.~3. Tubularisation of the flap: this stage procedure would be performed 6 months after the first procedure. Tubularisation of the the preputial flap will be done over a catheter. Byar's flaps may be created and transposed to cover the neourethra. Eventually, the penis will be dressed, and a urethral catheter will be retained for urinary diversion.
Study: NCT05267756

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: (kurki-application),VR glasses
Description: it is virtual reality immersive based-exercise game
Study: NCT06754644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 500 mg/m2 on Day 1 of each 21-day cycle of the study

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Target AUC of 5 mg/mL/min on Day 1 of each 21-day cycle up to 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Target AUC of 5 mg/mL/min on Day 1 of each 21-day cycle up to 4 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Keytruda®
Description: 200mg on day 1 of each 21-day cycle of the study
Study: NCT06754618

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Delfi
Description: Cuffs will be worn throughout the entire training session. Training session consist of lower intensity bicep curls. Four sets of wall squats will be performed to failure. Arterial stiffness and muscle morphological assessments will be conducted before and after the exercise.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Delfi
Description: Cuffs will be worn throughout the entire training session. Training session consist of lower intensity bicep curls. Four sets of wall squats will be performed to failure. Arterial stiffness and muscle morphological assessments will be conducted before and after the exercise.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Delfi
Description: Cuffs will be worn throughout the entire training session. Training session consist of lower intensity bicep curls. Four sets of wall squats will be performed to failure. Arterial stiffness and muscle morphological assessments will be conducted before and after the exercise.
Study: NCT06756113

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital Dyadic Empowerment
Description: The Digital Dyadic Empowerment Intervention utilizes LINE, a prominent instant messaging App in Taiwan, integrated with an extended application to deliver comprehensive lifestyle modification support to Chronic Kidney Disease (CKD) dyads. Key features of this intervention include:~1. Access to CKD Health Education Information;~2. Supportive Information for Significant Others;~3. Physiological Values Logging for Self-Monitoring;~4. Reminders for Clinical Appointments and Daily Self-Management Tasks;~5. Kidney Health Diary for Lifestyle Modification Progress Tracking;~6. Frequently Asked Questions (FAQs) and Consultation with Healthcare Providers.~This intervention aims to enhance the overall well-being of CKD dyads by promoting education, self-monitoring, adherence to appointments, and efficient communication with healthcare providers.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: All patients in this study received regular nephrology care at National Cheng Kung University Hospital. Nephrologists conducted routine examinations and provided diagnoses based on test results. The patient's condition (e.g., changes in kidney function), treatment plan, prognosis, and risks were explained to both the patient and family members. The treatment plan included medication, monitoring blood pressure, dietary and exercise at home, and consultations with the Health Education Center for kidney care or nutrition advice.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: All patients in this study received regular nephrology care at National Cheng Kung University Hospital. Nephrologists conducted routine examinations and provided diagnoses based on test results. The patient's condition (e.g., changes in kidney function), treatment plan, prognosis, and risks were explained to both the patient and family members. The treatment plan included medication, monitoring blood pressure, dietary and exercise at home, and consultations with the Health Education Center for kidney care or nutrition advice.
Study: NCT06754033

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Interventional group I
Description: Intervention Details: Participants in this arm will receive a Ganglion Impar Block, a minimally invasive injection aimed at blocking pain signals from the coccyx region (Ganglion Impar Block using Triamcinolone Acetate (40 mg) and Bupivacaine (0.25%) administered with a 22G Spinal Needle under Fluoroscopic Guidance). Participants in this arm will receive a Ganglion Impar Block, a minimally invasive procedure involving the administration of Triamcinolone Acetate (a corticosteroid) and Bupivacaine (a local anesthetic). This is intended to block pain signals originating from the coccyx region. The procedure will be conducted under fluoroscopic guidance to ensure precise delivery. The injection will be complemented by a structured physical therapy program, including heat therapy, ultrasound, posture training, core strengthening exercises, and mobility activities to improve pain relief and functional capacity.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Interventional group II
Description: Intervention Details: Participants in this arm will receive a Caudal Epidural Steroid Injection Caudal Epidural Steroid Injection using Triamcinolone Acetate (40 mg), Bupivacaine (0.25%), and Normal Saline (6 mL) administered with a 22G Spinal Needle under Fluoroscopic Guidance), designed to deliver anti-inflammatory medication directly to the epidural space, thereby reducing inflammation and pain. This will also be paired with a tailored physical therapy program, focusing on similar modalities as in Arm 1, including heat therapy, ultrasound, posture training, and strengthening exercises. The objective is to enhance pain relief and functional recovery in the context of coccydynia.
Study: NCT06752954

Intervention type: DEVICE
Intervention: Viabahn endoprosthesis group
Description: Viabahn endoprosthesis group：Patients underwent endovascular treatment for femoropopliteal lesions. The lesion will be treated by Viabahn endoprosthesis.

Intervention type: DEVICE
Intervention: Drug-coated balloon group
Description: Patients underwent endovascular treatment for femoropopliteal lesions. The lesion will be treated by drug-coated balloon.
Study: NCT06752980

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eye mask
Description: The three experimental groups (eye patch group, earplug group, eye patch and earplug group applied together) will be given a separate intervention during their night sleep on the 1st, 2nd and 3rd postoperative day. Repeated monitoring will be performed using RCUÖ and Nu-DESC on the 2nd, 3rd and 4th postoperative days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Earplugs
Description: The three experimental groups (eye patch group, earplug group, eye patch and earplug group applied together) will be given a separate intervention during their night sleep on the 1st, 2nd and 3rd postoperative day. Repeated monitoring will be performed using RCUÖ and Nu-DESC on the 2nd, 3rd and 4th postoperative days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eye Mask and Earplugs
Description: The three experimental groups (eye patch group, earplug group, eye patch and earplug group applied together) will be given a separate intervention during their night sleep on the 1st, 2nd and 3rd postoperative day. Repeated monitoring will be performed using RCUÖ and Nu-DESC on the 2nd, 3rd and 4th postoperative days.
Study: NCT06752551

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Apprehension-based training
Description: This intervention is comprised of the 3 phases:~Static phase - Isometric (static) exercises performed in progressively greater shoulder apprehension (instability) provoking conditions Dynamic phase: Isotonic (dynamic) exercises using shoulder apprehension-provoking movement patterns at a gradually increasing pace of movement.~Neurocognitive phase: Dynamic phase exercises are continued at a high pace with the addition of cognitive tasks (distractions).~The intervention is guided by a physical therapist and includes up to 4 individual (one on one) sessions. In each session the physical therapist assesses exercise performance quality and when appropriate progresses exercise intensity and/or phase. Patients are expected to perform home exercises according to their phase of the program on a daily basis in between physical therapy sessions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard physical therapy
Description: Standard physical will be provided based on the assessment and judgment of the physical therapist. Intervention may include active exercises for increased shoulder mobility, muscle strength and neuromuscular control. Intervention may also include manual therapies such as massage, soft-tissue and joint mobilizations, dry needling, and electrophysiological modalities. No more than 4 individual sessions with a physical therapist will be provided over the course of treatment with some form of a home exercise program in between.
Study: NCT06754631

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Continuous Nebulization of Salbutamol
Description: Children received continuous nebulization of salbutamol at a concentration of 0.3 mg/kg/hour for 4 hours, with a minimum of 5 mg/hour and a maximum of 15 mg/hour administered via High Output Extended Aerosol Respiratory Therapy (HEART).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intermittent Nebulization of Salbutamol
Description: were treated with intermittent nebulization of salbutamol at a dose of 0.15 mg/kg/dose, administered through a face mask with an oxygen flow rate of 6-8 L per minute. They Children received at least 2-3 nebulizations and no more than 7.5 mg/dose every 30 minutes for 4 hours.
Study: NCT06751186

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Teté Dance Guided Support
Description: A culturally tailored behavioral intervention combining physical activity and community engagement to support breastfeeding practices.
Study: NCT06756048

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rhomboid Intercostal Nerve Block
Description: Following standard ASA monitoring, patients were positioned on the surgical table with their backs facing the operator. Skin antisepsis was achieved using povidone. A high-frequency 8-18 MHz linear ultrasound probe was used.~After palpating the rhomboid muscles and intercostal spaces at the T6-T7 levels, the medial border of the scapula and the vertebral column were identified. The ultrasound probe was placed horizontally along the medial border of the scapula. Using ultrasound guidance, the ribs, rhomboid muscles, intercostal muscles, and pleura were visualized. Once these anatomical structures were clearly identified, a 50 mm, 22G regional block needle was advanced in-plane from caudal to cranial under ultrasound guidance until the interfascial plane beneath the rhomboid muscles was reached and total of 20 ml of 0.25% bupivacaine (Marcaine® 0.5%, AstraZeneca PLC, London, UK) was injected.
Study: NCT06756022

Intervention type: DRUG
Intervention: Dolasetron mesylate injection
Description: 1.8 mg/kg Dolasetron mesylate injection should be injected intravenously 30±10 min before chemotherapy infusion, with the maximum dose not exceeding 100 mg. It can also be mixed with apple juice or apple-grape juice for oral use, the oral dose is 1.8 mg/kg, the maximum amount is not more than 100 mg, taken orally within 1 h before chemotherapy.~Other antiemetic drugs, except dolasetron, are at the discretion of the subject's supervising physician in accordance with clinical practice.
Study: NCT06753383

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: To the Virtual Reality Based Exercise
Description: After posterior fusion surgery, a rehabilitation program will be applied to individuals with AIS using Kinect Sports Ultimate for 30 minutes per day for a total of 6 weeks, 2 days a week.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine physiotherapy and rehabilitation program
Description: 14 patients with posterior fusion AIS routinely in the postoperative clinic for 6 weeks. the physiotherapy program used will be applied.
Study: NCT06752083

Intervention type: DIETARY_SUPPLEMENT
Intervention: AHCC® (Active Hexose Correlated Compound)
Description: 3 capsules of AHCC® daily for 4-6 months to support immune modulation and promote HPV negativity.

Intervention type: DIETARY_SUPPLEMENT
Intervention: AHCC® (Active Hexose Correlated Compound)
Description: 3 capsules of AHCC® daily for 4-6 months to support immune modulation and promote HPV negativity.

Intervention type: BIOLOGICAL
Intervention: Gardasil 9®
Description: Administration of the nonavalent HPV vaccine to provide protection against high-risk HPV genotypes.

Intervention type: BIOLOGICAL
Intervention: Gardasil 9®
Description: Administration of the nonavalent HPV vaccine to provide protection against high-risk HPV genotypes.
Study: NCT06752707

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MiGo Tracker
Description: Perform home exercise sessions while wearing MiGo Tracker device that logs exercise data.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional home exercise program
Description: Exercise following printed sheets or booklet
Study: NCT06754397

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic Resonance Cholangiopancreatography
Description: Three most important sequences included axial T2 weighted scan from liver to ampullary region followed by T2 weighted 3D FSE sequence acquired in coronal oblique plane using respiratory triggering by tying bellows over abdomen. After this breath hold HASTE sequence is acquired in coronal plane. Maximum intensity projection (MIP) and thick slab images are also used for interpretation. US, CECT and MRCP scans are interpreted by radiologists blinded to other imaging findings
Study: NCT06008405

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2928 Injection + Azacitidine for injection
Description: TQB2928 injection is a fully humanized Immunoglobulin G 4 (IgG4) subtype monoclonal antibody targeting CD47.~Azacitidine for injection is a nucleoside metabolism inhibitor that inhibits DeoxyriboNucleic Acid (DNA) methyltransferase, reduces DNA methylation and alters gene expression.
Study: NCT05900661

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: myo-inositol
Description: myo-inositol 600µgm + folic acid 0.2 mg) 2 capsules at the morning and 2 capsules at the evening on empty stomach for 12 weeks produced by a Lo.Li pharma international ,Rome.Italy .

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Somatropin
Description: growth hormone 2:Somatropin (4 IU for 1month), SEDICO ,6th of october .Egypt. 1 s.c injection every 3 days for at least 1 month.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dehydroepiandrosterone
Description: DHEA 50 mg twice per day for 12 weeks in the last group , NATROL UK.Ltd.
Study: NCT06524791

Intervention type: OTHER
Intervention: bacteriophage detection
Description: bacteriophage detection

Intervention type: OTHER
Intervention: bacteriophage detection
Description: bacteriophage detection
Study: NCT04711629

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical Tests
Description: Respiratory function test, arterial blood gas analysis, six-minute walking test (6-MWT), mMRC Dyspnea Scale, St George Quality of Life Questionnaire and Hospital Anxiety Depression Scale

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical Tests
Description: Respiratory function test, arterial blood gas analysis, six-minute walking test (6-MWT), mMRC Dyspnea Scale, St George Quality of Life Questionnaire and Hospital Anxiety Depression Scale
Study: NCT06754111

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ideal birth environment
Description: ideal birth room While designing a single room without unnecessary medical equipment, your own bed linen, bed linen, It will be a pillow case, a photo frame, he will be able to listen to the music he wants, he will be able to make a photo of his own choice.~There will be a companion, a birthing ball and chair, and the room will allow freedom of movement.~It will be designed to allow